SYMBYAX
LOE ApproachingNDAORALCAPSULEPriority Review
Approved
Dec 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 22h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SYMBYAX is an oral capsule combination product approved by Eli Lilly in December 2003. The drug treats psychiatric indications as a small-molecule formulation. Specific mechanism of action and clinical indications are not disclosed in available data.
$65KPart D
LOE ApproachingProduct approaching loss of exclusivity with minimal Part D spending ($65K) and low claim volume (134 claims in 2023), indicating a mature product with likely declining team investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job opportunities reflect the product's late-lifecycle stage and minimal commercial expansion. Careers tied to SYMBYAX are in managed-decline mode, with focus on maintaining existing market share rather than growth initiatives.
Brand ManagerField Sales Representative
Worked on SYMBYAX at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.